Skip to Content

Neose Announces Data Presentations on GlycoPEGylated Factor VIIa at the American Society of Hematology Annual Meeting

HORSHAM, Pa.--(BUSINESS WIRE)--Nov 20, 2007 - Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that two abstracts regarding preclinical data for GlycoPEGylated recombinant Factor VIIa will be presented in a poster session at the American Society of Hematology's 49th Annual Meeting and Exposition taking place in Atlanta, Georgia from December 8-11, 2007. GlycoPEGylated Factor VIIa is being developed by Novo Nordisk under a license agreement with Neose and is currently in Phase I.

The abstracts are as follows:

-- Platelet-Dependent Activity of GlycoPEGylated rFVIIa (Abstract #3140, co-authored by Novo Nordisk and Neose)

-- Activity and Regulation of Long-Acting Factor VIIa Analogs (Abstract #3141, co-authored by Novo Nordisk and The University of Texas Health Center)

Both posters are being presented in the Poster Session titled, Coagulation-Based Therapeutics and Assays, being held on December 10 from 5:00 - 7:00 p.m.

The abstracts are available on the American Society of Hematology website at The posters will be made available on the Neose website following the poster session.

About Coagulation Factor VII

Factor VII/VIIa is used in the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients with congenital hemophilia with inhibitors to coagulation factors VIII or IX. The worldwide market for recombinant Factor VII was approximately $1 billion in 2006, with Novo Nordisk being the only participant.

About Neose Technologies, Inc.

Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market, on its own and through strategic partnerships. The lead candidates in its pipeline, NE-180 for use in the treatment of chemotherapy-induced anemia and anemia associated with chronic kidney disease and GlycoPEG-GCSF for chemotherapy-induced neutropenia, target markets with aggregate sales in excess of $15 billion. For more information, please visit

Neose "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: There are statements in this press release regarding our business that are "forward-looking statements" that involve risks and uncertainties. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the sections of Neose's Annual Report on Form 10-K for the year ended December 31, 2006, entitled "Risk Factors" and "Special Note Regarding Forward-Looking Statements" and discussions of potential risks and uncertainties in Neose's subsequent filings with the SEC.


Neose Technologies, Inc.
A. Brian Davis
Sr. Vice President and Chief Financial Officer
Barbara Krauter
Manager, Corporate Communications

Posted: November 2007